CN1345728A - Solasodine hydrochlorate and productive method and application in medicine - Google Patents
Solasodine hydrochlorate and productive method and application in medicine Download PDFInfo
- Publication number
- CN1345728A CN1345728A CN 00129122 CN00129122A CN1345728A CN 1345728 A CN1345728 A CN 1345728A CN 00129122 CN00129122 CN 00129122 CN 00129122 A CN00129122 A CN 00129122A CN 1345728 A CN1345728 A CN 1345728A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- hydrochloride
- crystallization
- solasodine
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims description 11
- KWVISVAMQJWJSZ-VKROHFNGSA-N solasodine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CN1 KWVISVAMQJWJSZ-VKROHFNGSA-N 0.000 title description 13
- JXWLYDNHVXFBJA-UHFFFAOYSA-N solasodine Natural products CC1CCC2(NC1)NC3CC4C5CC=C6CC(O)CCC6(C)C5CCC4(C)C3C2C JXWLYDNHVXFBJA-UHFFFAOYSA-N 0.000 title description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 28
- 238000002347 injection Methods 0.000 claims abstract description 14
- 239000007924 injection Substances 0.000 claims abstract description 14
- 208000006673 asthma Diseases 0.000 claims abstract description 10
- -1 compound solasodine hydrochloride Chemical class 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 92
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 78
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 42
- 238000002425 crystallisation Methods 0.000 claims description 40
- 230000008025 crystallization Effects 0.000 claims description 40
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 240000002307 Solanum ptychanthum Species 0.000 claims description 18
- 235000002594 Solanum nigrum Nutrition 0.000 claims description 17
- 229930013930 alkaloid Natural products 0.000 claims description 15
- 235000015203 fruit juice Nutrition 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 9
- 244000061458 Solanum melongena Species 0.000 claims description 8
- 235000002597 Solanum melongena Nutrition 0.000 claims description 8
- 230000001093 anti-cancer Effects 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 235000021559 Fruit Juice Concentrate Nutrition 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000007670 refining Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 230000001741 anti-phlogistic effect Effects 0.000 claims 1
- 238000013375 chromatographic separation Methods 0.000 claims 1
- 235000019628 coolness Nutrition 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- GSRSOTGLOHUAGA-XBODYBRHSA-N solasodine hydrochloride Chemical compound Cl.O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CN1 GSRSOTGLOHUAGA-XBODYBRHSA-N 0.000 description 53
- 230000000694 effects Effects 0.000 description 17
- 239000007788 liquid Substances 0.000 description 16
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- QCTMYNGDIBTNSK-UHFFFAOYSA-N Solasonin Natural products O1C2(NCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C1OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O QCTMYNGDIBTNSK-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000001088 anti-asthma Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 4
- 206010044008 tonsillitis Diseases 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QCTMYNGDIBTNSK-XEAAVONHSA-N α-Solamarine Chemical group O([C@H]1[C@@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QCTMYNGDIBTNSK-XEAAVONHSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- MBWUSSKCCUMJHO-ZGXDEBHDSA-N Solamargine Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O MBWUSSKCCUMJHO-ZGXDEBHDSA-N 0.000 description 3
- MBWUSSKCCUMJHO-DVDUUUGDSA-N Solamargine Natural products O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@@H](C)[C@@]6(O[C@H]5C4)NC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](C)O1 MBWUSSKCCUMJHO-DVDUUUGDSA-N 0.000 description 3
- KNLOWJPFLKGYGQ-UHFFFAOYSA-N Solasodine 3-O-??-L-rhamnopyranosyl (1‘Â∆2)-O-[??-D-glucopyranosyl (1‘Â∆4)]-??-D-glucopyranoside Natural products O1C2(NCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(CO)C(O)C(O)C1O KNLOWJPFLKGYGQ-UHFFFAOYSA-N 0.000 description 3
- QCTMYNGDIBTNSK-QCNFCIKQSA-N Solasonine Natural products O([C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O[C@@H]2CC=3[C@@](C)([C@@H]4[C@H]([C@H]5[C@@](C)([C@H]6[C@@H](C)[C@@]7(O[C@H]6C5)NC[C@H](C)CC7)CC4)CC=3)CC2)O[C@@H](CO)[C@@H]1O)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QCTMYNGDIBTNSK-QCNFCIKQSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- RCTKRNCKOYYRIO-UHFFFAOYSA-N alpha-Solamarine Natural products O1C2(NCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C1O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O RCTKRNCKOYYRIO-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 102000011759 adducin Human genes 0.000 description 2
- 108010076723 adducin Proteins 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 240000007776 Solanum aviculare Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- WUEXFSVOXPGVML-UHFFFAOYSA-N ethanol;pentane Chemical compound CCO.CCCCC WUEXFSVOXPGVML-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a new compound solasodine hydrochloride with the functions of resisting cancer, resisting inflammation and relieving asthma. Said invention also provides its molecular structure and production process, and its application of two dosage forms of oral liquor and injection in medicine.
Description
The present invention relates to a kind of new compound solasodine hydrochloride and production method thereof and in pharmaceutically application.
Existing black nightshade and the Chemical Composition of Australian eggplant, the separation method of solasodine and the research of drug activity both at home and abroad, solasodine is water insoluble, is dissolved in methyl alcohol, chloroform and hot ethanol, has anti-inflammatory, anti-S
180, rising blood sugar effect, toxic side effect is big, content is low, is pharmaceutically using as yet so far, its four kinds of glycosides account for more than 80% of total alkali, no anticancer, anti-inflammatory action only uses as sterilant on agricultural.Its leaching process complexity, agents useful for same is many, danger is big, seriously polluted, production cycle length, separation difficulty, can't use.
It is strong to the purpose of this invention is to provide a kind of drug activity, toxic side effect is little, water soluble, stable in properties, new compound solasodine hydrochloride and production method thereof that production method is easy, and as a kind of source new drugs in pharmaceutically application, to replace those weak curative effects, the existing medicine that toxic side effect is big benefits the people.
Principle of the present invention be according to the structure activity relationship of medicine will not have anticancer, relieving asthma, four kinds of glycosides α-solasonines, β-solasonine, γ-solasonine, the solamargine hydrolysis of the solasodine of anti-inflammatory activity, make the alkaloid that becomes unbound state with the alkaloid of sugared bonding state, make its generation have 3-hydroxyl anticancer, anti-inflammatory activity.Again with the secondary amino group salify on the 6th ring in the molecule, the drug activity group on its molecule precursor structure that polarizes by force makes anticancer, the antiphlogistic drug activity of its maintenance and enhancing 3-hydroxyl, and the polarity of its molecule, solvability, stability strengthen simultaneously.Activate its molecule drug activity, with the secondary ammonium alkali that causes on 3-hydroxyl and the 6th ring, two active groups coexist as with the constructional feature among a part, and two active groups interact, and make its molecule produce new drug activity antiasthmatic effect again.
Its reaction is as follows:
1, compound solasodine hydrochloride of the present invention has following structure and nature and characteristic:
(1) molecular structure of solasodine hydrochloride:
Molecular formula: C
27H
44NO
2Cl molecular weight: 448.08
(2) physico-chemical property solasodine hydrochloride is a kind of trilateral sheet crystallization (ethanol), and 300 ℃ do not reach the preceding decomposition of fusing point, [α] 20
D=-2.2 (water), soluble in water, acetic acid solution, be insoluble to high density methyl alcohol, ethanol, be insoluble to organic solvents such as acetone, benzene, ether, sherwood oil.
(3) drug activity
1. antitumour activity solasodine hydrochloride 200mg/kg can significantly suppress nuclear fission, can make HeLa cytoclasis to behind mice transplanted tumor inhibiting rate 〉=65%, 12 hour, and obvious cytotoxicity is arranged.Clinical trial certificate, injection concentration are 50mg/ml, and the 10-30ml solasodine hydrochloride aqueous solution is to lung cancer, liver cancer, mammary cancer, and 7-10 obtains obvious effects in day.Cooperate operation medication curative effect better.
2. antiasthmatic activity solasodine hydrochloride 150mg/kg, oral or abdominal injection, the cavy asthma that can significantly bring out to antihistaminic.Clinical trial certificate, capsule that the solasodine hydrochloride is made or tablet, every,, contain solasodine hydrochloride 100mg only, day is obeyed secondary, each 2-3 sheet, grain, dyspnea disappears or obviously disappears in 20-30 minute, and vital capacity obviously increases, toot the sound of roaring obviously reduces, and complexion, breathes and drives in normally.Heavily suffer from 2-3 and can normally walk down in day, blood pressure, heart are also made moderate progress.
3. anti-inflammatory activity solasodine hydrochloride 150mg/kg filling stomach or abdominal injection can significantly resist the mouse foot swelling that carrageenin causes; Clinical trial certificate, tablet that the solasodine hydrochloride is made or capsule, every, contain solasodine hydrochloride 100mg only, day is obeyed secondary, each 2-3 sheet, grain, white corpuscle in the pneumonia, pulmonary tuberculosis, mazoitis, tonsillitis, pharyngitis, trachitis three days is obviously reduced, and inflammation obviously disappears, and 4-7 drives in day substantially in normally.
2, the production method of solasodine hydrochloride
Of the present invention a kind of have more anticancer, relieving asthma, the production method of Chinese medicine one kind new medicine source solasodine (Salasadine) hydrochloride of anti-inflammatory activity, be that life, the half ripe with Solanaceae nightshade black nightshade (Salanum NigrumL) and Australian eggplant (Salanum aviculare Farst) really is raw material.
Accompanying drawing 1 is the process flow sheet of production method of the present invention, below in conjunction with accompanying drawing in detail production method of the present invention is described in detail:
(1) with the production method of national inventing patent " production method of the concentrated black nightshade fruit juice " patent No.: ZL 94104239.1 patentee Liu Liang: with black nightshade or Australian eggplant give birth to fruit or the half ripe fruit is pressed juice through fragmentation, juice, slag separate, thick juice is through acidic ethanol extraction, sedimentation or smart filter, concentrating under reduced pressure or add enzymic hydrolysis, sterilization, acidic ethanol extraction, sedimentation or smart filter, concentrating under reduced pressure; Pomace is made concentrated black nightshade fruit juice or Australian eggplant fruit juice concentrate with acidic ethanol leaching back separation, immersion liquid sedimentation or smart filter concentrating under reduced pressure.
(2) the colloid thing in the separation fruit juice concentrate: add 4-8 doubly 60-100% ethanol or the methyl alcohol and the high degree of agitation of (volume) amount to concentrated black nightshade fruit juice or Australian eggplant fruit juice concentrate, make solution be cream-coloured till the muddy liquid of tawny, supernatant liquor is got in placement, sedimentation.
(3) extraction of thick total alkaloids hydrochloride: the extraction of thick total alkaloids hydrochloride has two kinds of methods:
1. supernatant liquor concentrating under reduced pressure, bath temperature 40-90 ℃, vacuum tightness 0.08-0.095Mpa is to chocolate viscous liquid proportion 1.09-1.45g/ml, get secondary concentration fruit juice, secondary concentration fruit juice is placed cooling fold the crystallization of thick total alkaloids hydrochloride in room temperature or refrigerator.
2. supernatant liquor is put in room temperature or-a 10-20 ℃ refrigerator internal cooling separates out the crystallization of thick total alkaloids hydrochloride, leach crystallization, filtrate decompression is concentrated into the chocolate viscous liquid, cooling folds crystallization, the ethanol or the methyl alcohol that in containing crystalline secondary concentration fruit juice, add 80-100% again, stirring makes solution to the turbidity maximum, place sedimentation, get supernatant liquor, in fully leaching crystallization after the cooling under the-10-20 ℃ temperature, crystallization is with 80-100% ethanol or methanol wash 2-3 time, suction strainer, dry must slightly total biological crystal of hydrochloride.
(4) refining: that thick total alkaloids hydrochloride is carried out recrystallization with ethanol or first alcohol and water, get total alkaloids hydrochloride elaboration, main component is α-solasonine hydrochloride, β-solasonine hydrochloride, γ-solasonine hydrochloride, solamargine (solamargine) hydrochloride, solasodine (solanidine-S) hydrochloride.For soluble in water, the crystal of insoluble high concentration ethanol, methyl alcohol.
(5) hydrolysis: with the total alkali hydrochloride with the dissolving of the aqueous hydrochloric acid of 2.5-8% or to transfer to ethanol or methyl alcohol with the 2.5-8% hydrochloric acid soln that adds ethanol or methyl alcohol after the little water dissolving earlier be that the solution of 2.5-8% hydrochloric acid of 50-80% is solid: liquid (1: 20-100), heating in water bath is to boiling 2 hours, adding 80-100% ethanol or methyl alcohol while hot separates out as the solasodine crystal of hydrochloride, stop to add alcohol, being heated to boils makes the crystallization dissolving, as do not dissolve add less water and make it all dissolvings till, to boiling, stop heating, cooling, or the cooling back adds up activated carbon decolorizing or the absorption impurity of the 1-5% of alkali salt hydrochlorate input amount, to the five minutes heat filterings that boil, filtrate is cooled off down in normal temperature and is separated out the solasodine crystal of hydrochloride, to be crystallizedly separate out fully, leach crystallization, with 80-100% ethanol or methanol wash 1-3 time, dry thick solasodine crystal of hydrochloride.
(6) throw out is handled: throw out dissolves with little water, adds 60-100% ethanol or methyl alcohol to muddy, and quiescent settling is got supernatant liquor and is evaporated to thick shape, adds 80-100% ethanol or methyl alcohol, places and separates out crystallization, and filtrate concentrating adds alcohol till do not have crystallization again and separate out.
(7) refining: as to get solasodine hydrochloride elaboration with ethanol or first alcohol and water recrystallization.
Also available solasodine hydrochloride column chromatography for separation method is refining, and concrete operations are as follows:
With 1.0g solasodine hydrochloride and 5g silica gel G mixing, tablet forming, separator column is with (4: 3) benzene: methyl alcohol is washed post, sheet is put in the separator column top of being equipped with through 1 hour silica gel G of 110 ℃ of activation, use benzene: methyl alcohol (4: 3) developping agent, flow velocity 2 seconds/(using vacuum degree control) launches the back chromatographic column and chromatographic band clearly occurs.With 50% ethanol is eluent, and repeated isolation is collected each chromatographic band effluent liquid as stated above, and each effluent liquid of concentrating under reduced pressure gets a kind of white crystal.
The solasodine hydrochloride is a kind of easy molten water, acetic acid, low-concentration ethanol, lower concentration methyl alcohol, is insoluble to the white triangles shape tabular crystal (ethanol) of acetone, chloroform, ethyl acetate, benzene, stable in properties.
With solasodine hydrochloride purity 〉=90% that aforesaid method is produced, yield (dry product calculating) 〉=1.2%, solasodine hydrochloride structure is:
Fusing point, the preceding 300 ℃ of decomposition of fusing point.
3, the solasodine hydrochloride is in pharmaceutically application
(1) antitumous effect solasodine hydrochloride 200mg/kg can significantly suppress nuclear fission, can make HeLa cytoclasis to behind animal transplanting tumor inhibiting rate 〉=65%, 12 hour, and obvious cytotoxicity is arranged; Clinical experiment shows, solasodine hydrochloride 50mg/ml, and the 10-30ml injection liquid, evident in efficacy to lung cancer, liver cancer, mammary cancer.
(2) anti-inflammatory action solasodine hydrochloride 100mg/kg mouse stomach, abdominal injection can obviously resist sufficient the swelling of mouse that carrageenin causes; Clinical trial certificate, the solasodine hydrochloride is to pneumonia, pulmonary tuberculosis, mazoitis, tonsillitis, pharyngitis, trachitis injection or oral, and daily 2 times, solasodine hydrochloride net weight 〉=300mg is evident in efficacy at every turn.
(3) antiasthmatic effect solasodine hydrochloride 150mg/kg can significantly bring out cavy asthma to antihistaminic; Face to treat and experimental results show that, oral or injection day medication 2-3 time, only contain solasodine hydrochloride 200-300mg at every turn, to the onset in 15-30 minute of immunity asthma, working lipe 〉=24 hour, heavily suffer from the walking of can leaving the bed in 2-3 days, dyspnea on most beds, wheezing sound disappears or disappear substantially, vital capacity obviously increases, medication is clearly better 7 days (course of treatment), coughs, phlegm, inflammation obviously alleviates or disappear.
The solasodine hydrochloride is a kind of Chinese medicine one kind new medicine with significantly anticancer, anti-inflammatory, antiasthmatic effect, and its purposes is mainly used in the medicine manufacturing of the following disease of treatment:
(1) manufacturing of cancer therapy drug:
1. treat the injection manufacturing of liver cancer, lung cancer, mammary cancer.
2. treat the oral preparations manufacturing of liver cancer, lung cancer, mammary cancer.
(2) manufacturing of suppressing panting calming medicine:
1. the injection manufacturing of anti-immune asthma
2. the manufacturing of anti-immune asthma oral preparations
(3) manufacturing of anti-inflammatory drug
1. treat the injection manufacturing of pneumonia, pulmonary tuberculosis, trachitis, tonsillitis, mazoitis, pharyngitis.
2. treat the oral preparations manufacturing of pneumonia, pulmonary tuberculosis, trachitis, tonsillitis, mazoitis, pharyngitis.
In sum, solasodine hydrochloride of the present invention is crystallization soluble in water, stable in properties, have extremely strong anticancer, anti-inflammatory, the isoreactivity of relievining asthma, toxic side effect is little, can be used for the pharmacy of multiple formulation, helps using, the production technique of solasodine hydrochloride is easy and simple to handle, Device-General, agents useful for same is nontoxic, and valency is low easily to be reclaimed, with short production cycle, be beneficial to Application and Development.
Embodiment 1: take by weighing that the 500kg black nightshade gives birth to, half ripe really removes foreign material, use the pulverizer fragmentation, add hydrochloric acid 95% ethanol of 200kg PH1-2, stirs after 30 minutes placement leach 4 hours centrifugal, tell acid immersion liquid.Pomace is again with the hydrochloric acid 95% ethanol leaching of 100kg PH1-2, centrifugally tells immersion liquid, and pomace is shone dry grinding and makees feed and use.Merge twice acidic ethanol immersion liquid, place sedimentation 24 hours, get the supernatant liquor concentrating under reduced pressure, 70 ℃ of bath temperatures, vacuum tightness 0.09Mpa heats up in a steamer ethanol before the recovery, and being concentrated into proportion is 1.26mg/ml, brownish black viscous liquid, gets concentrated black nightshade fruit juice 41kg.
In being the concentrated black nightshade fruit juice of 1.26mg/ml, proportion adds in the 250kg95% ethanol thread slowly and high degree of agitation, be emulsion to solution, normal temperature was placed 3-4 hour down, get supernatant liquor, in-10-20 ℃ refrigerator and cooled but 24 hours, the crystallization of black nightshade total alkaloids hydrochloride is fully separated out, and suction strainer is told crystallization, and filtrate decompression is concentrated into viscous liquid and gets secondary concentration fruit juice 15kg.In secondary concentration fruit juice, add 60-80% and reclaim ethanol 50kg, stirring constantly separates out the crystallization of dark brown mucolysis black nightshade total alkaloids hydrochloride, be put in but (condition is the same) filtration of refrigerator and cooled, suction strainer, tell coarse crystallization, crystallization is with 95% washing with alcohol three times, thick black nightshade total alkaloids hydrochloride crystallization 2140g.
Make with extra care 2140g black nightshade total alkaloids hydrochloride crude product is put in 50L
3In the ceramic jacket reactor, add 15.0L
3Water makes it dissolving, adding 95% ethanol to crystallization separates out, being heated to boils just dissolves crystallization, stop the heating being cooled to 40-45 ℃, add gac 500g, be heated to boiled 5 minutes after, heat filtering, cooling is to be crystallizedly separated out complete suction strainer with the 5000ml95% washing with alcohol once, dry black nightshade total alkaloids hydrochloride 1640g elaboration.
Hydrolysis is dissolved in 500L with 1640g black nightshade total alkaloids hydrochloride elaboration with the 10L3 5%HCl aqueous solution
3In the ceramic jacket reactor, add the 80% ethanol 50L that contains 5% hydrochloric acid
3Be heated to and boil 2 hours, adding 95% ethanol to crystallization while hot in still separates out, be heated to and boil, transferred to a little crystallization insoluble till, till adding little water crystallization just being dissolved, be cooled to room temperature, leach crystallization, and with 5000ml 95% washing with alcohol once, the dry solasodine hydrochloride coarse crystallization 991g that gets.
Refining 991g solasodine hydrochloride is dissolved in the 5000ml water, is put in 50L
3In the still, add 95% ethanol to crystallization and separate out, be heated to and boil, make the crystallization dissolving, add 95% ethanol to crystallization again and separate out to be heated to and boil, crystallization is no longer dissolved, and adds a little crystallization dissolving filtered while hot just of water, filtrate is cooled to room temperature, suction strainer, with 95% ethanol 1000ml washing 2 times, dry under room temperature, weighing gets 625g solasodine hydrochloride elaboration, and the envelope bottle is preserved in refrigerator.Productive rate is 1.25%, and calculating productive rate by dry product is 1.25%.
Solasodine hydrochloride column chromatography for separation
With 1.0g solasodine hydrochloride and 5g silica gel G mixing, tablet forming, (separator column (4: 3) benzene: methyl alcohol is washed post) is put in the separator column top of being equipped with through 1 hour silica gel G of 110 ℃ of activation respectively, use benzene: methyl alcohol (4: 3) developping agent, flow velocity 2 seconds/(using vacuum degree control) launches the back chromatographic column and chromatographic band clearly occurs.With 50% ethanol is eluent, and repeated isolation is collected the chromatographic band effluent liquid as stated above, and each effluent liquid of concentrating under reduced pressure gets a kind of white crystal.
Embodiment 2: get that Australian eggplant is given birth to and half-mature fruit 500kg to extract the method for preparing the solasodine hydrochloride from Fructus Solani Nigri identical by above-mentioned, must 611g solasodine hydrochloride elaboration.Productive rate 1.22% is pressed dry product and is calculated productive rate 1.22%.
From two kinds of different raw materials, extract the solasodine hydrochloride silica gel G F for preparing with aforementioned production method
254Plate, benzene: methyl alcohol (4: 3) is developping agent, go in UV-light=254nm under, each a spot, R occur
fValue=0.67 illustrates that every kind of raw material extracts, and the crystallization of preparation is a kind of compound, and two kinds of crystallizations are same substances.
Detect the solasodine hydrochloride with following method:
1. high performance liquid chromatography:
The solasodine hydrochloride aqueous solution is transferred to alkalescence with 5N NaOH, use dichloromethane extraction,, be used to do following experiment after the drying with anhydrous sodium sulfate drying extraction liquid, concentrating under reduced pressure.
Sample after above-mentioned processing by containing the Waters Seppak C18 decontaminating column (Cartrdges) of BondapakC18, is used following condition analysis with the dissolve with methanol of 40% (V/V):
(1) solasodine hydrochloride and solasonine hydrochloride
(temperature is 25 ℃, detects at UV205 for 30CM * 3.9mmi.d.) annotate moving phase with methyl alcohol-0.01M Tris buffered soln (75: 25), flow velocity 2ml/mim at μ BondapaK18.Fig. 2, Fig. 3 provide the standard collection of illustrative plates, Fig. 2 is the chromatography collection of illustrative plates of solasonine and solanidine-S, 1 α among the figure-solasonine, 2 β-solasonine, 3 γ-solasonine, 4 solanidine-Ss, Fig. 3 is the chromatography collection of illustrative plates of solasonine, 1 α among the figure-solasonine, 2 β-solasonine, 3 γ-solasonine.Detected result: appearance time 15min, purity 90.4%.
(2) mensuration of solasodine hydrochloride:
With ethanol-pentane (4: 1) dissolving solasodine (above-mentioned sample is after treatment determined solasodine hydrochloride content with the content of high-efficient liquid phase analysis solasodine) chromatography column 30cm * 4.6cm, load Zorbax SLL (6 μ m), other is furnished with the long pre-column of filling poasilA (37-75 μ m).Moving phase is-hexane: methyl alcohol: acetone (18: 1: 1) flow velocity is imitated ml/min.
Embodiment 3: with the smart purity that claims of balance is 97% solasodine hydrochloride 103.10g, and porphyrize is with mixing behind the heavy powder 30g porphyrize of lactose 67g solubility; Be divided into two parts, every part of each 100g, 100g tabletting machine compressing tablet wherein, every 200mg, get 497 of solasodine hydrochloride sheets, use the plastic-aluminum shrouding, the capsule packing, 24 in every box, every contains solasodine hydrochloride reactive monomer 〉=100mg only, gets solasodine hydrochloride tablet 20 boxes.100g can capsule in addition, every 200mg, 499 of solasodine hydrochloride capsules, pack with plastic-aluminum shrouding, capsule, 24 in every box, every contains solasodine hydrochloride reactive monomer 〉=100mg only, gets solasodine hydrochloride capsule 20 boxes.
Embodiment 4: the smart 103.10g purity that claims is 97% solasodine hydrochloride, under aseptic, be loaded in the peace bottle, every bottle of 515.5mg, the envelope bottle, used peace bottle capacity is 30ml ± 1ml, gets 200 bottles of solasodine hydrochloride injections, the capsule packing, 10 in every box, every contains solasodine hydrochloride reactive monomer 〉=500mg only, gets solasodine hydrochloride injection 20 boxes.
Claims (3)
1, the solasodine hydrochloride compound of a kind of following general formula (I):
2, according to the production method of the compound of claim 1, this method may further comprise the steps:
(1) be raw material with the life of black nightshade or Australian eggplant, half-mature fruit, with patent of invention " production method of black nightshade dope fruit juice " patent No. ZL 94104239.1, the production method of patentee Liu Liang is made concentrated black nightshade fruit juice or Australian eggplant fruit juice concentrate;
(2) the colloid thing in the separation fruit juice concentrate: add 4-8 doubly the 60-100% ethanol or the methyl alcohol of (volume) amount to fruit juice concentrate, be stirred to till the fruit juice muddiness;
(3) extracting method of thick total alkaloids hydrochloride has two kinds of methods:
1. supernatant liquor is evaporated to proportion 1.09-1.45g/ml, room temperature placement or refrigerator and cooled are but placed and are separated out crystallization;
2. supernatant liquor is placed or-10～20 ℃ of coolings down in room temperature, told crystallization, filtrate decompression is concentrated add alcohol to precipitation again, crystallization is told in the supernatant liquor cooling again, precipitates ethanol or methyl alcohol that used alcohol is 80-100%;
(4) refining water and ethanol or recrystallizing methanol;
(5) hydrolysis is with 2.5～8% aqueous hydrochloric acid, also available ethanol or the methanol solution that contains the hydrochloric acid 50-80% of 2.5-8%, separated out crystallization in 2 hours to boiling, with ethanol or first alcohol and water to saturated separate out crystallization or add activated carbon to boiling hot filtration postcooling after saturated separate out crystallization;
(6) throw out is handled and use water dissolution, adds 60-100% ethanol or methyl alcohol and precipitates once more, adds the alcohol placement behind the supernatant liquor concentrating under reduced pressure and separates out crystallization, till repeating to be extracted into no crystallization and separating out;
(7) refining with ethanol or first alcohol and water recrystallization, also available silica gel G chromatographic separation is purified, and used developping agent is a benzene: methyl alcohol (4: 3), eluent are 50% ethanol.
3, according to claim 1 compound, medicine such as that this compound is applied to is anticancer, relieving asthma, antiphlogistic oral preparations and injection are made.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00129122 CN1107680C (en) | 2000-09-29 | 2000-09-29 | Solasodine hydrochlorate and productive method and application in medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00129122 CN1107680C (en) | 2000-09-29 | 2000-09-29 | Solasodine hydrochlorate and productive method and application in medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1345728A true CN1345728A (en) | 2002-04-24 |
| CN1107680C CN1107680C (en) | 2003-05-07 |
Family
ID=4593304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00129122 Expired - Fee Related CN1107680C (en) | 2000-09-29 | 2000-09-29 | Solasodine hydrochlorate and productive method and application in medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1107680C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1329038C (en) * | 2003-06-20 | 2007-08-01 | 德英生物科技股份有限公司 | Water soluble nightshade extract, its preparation method and pharmaceutical compositions |
| CN100340570C (en) * | 2003-11-29 | 2007-10-03 | 刘良 | Solasodine salt of organic acid, its preparation method and application in medicine |
| CN102643326A (en) * | 2012-04-25 | 2012-08-22 | 广东固升医药科技有限公司 | 3,6-dihydroxyl-22(27)imino-4-furan sterene and preparation method and application thereof |
| JP2020203856A (en) * | 2019-06-17 | 2020-12-24 | 株式会社ダイセル | Method for producing tomatidine-containing extract |
| CN114848663A (en) * | 2022-05-09 | 2022-08-05 | 河南省人民医院 | Application of natural compound Solamargine and anti-HBV (hepatitis B virus) pharmaceutical composition |
-
2000
- 2000-09-29 CN CN 00129122 patent/CN1107680C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1329038C (en) * | 2003-06-20 | 2007-08-01 | 德英生物科技股份有限公司 | Water soluble nightshade extract, its preparation method and pharmaceutical compositions |
| CN100340570C (en) * | 2003-11-29 | 2007-10-03 | 刘良 | Solasodine salt of organic acid, its preparation method and application in medicine |
| CN102643326A (en) * | 2012-04-25 | 2012-08-22 | 广东固升医药科技有限公司 | 3,6-dihydroxyl-22(27)imino-4-furan sterene and preparation method and application thereof |
| CN102643326B (en) * | 2012-04-25 | 2014-03-26 | 广东固升医药科技有限公司 | 3,6-dihydroxyl-22(27)imino-4-furan sterene and preparation method and application thereof |
| JP2020203856A (en) * | 2019-06-17 | 2020-12-24 | 株式会社ダイセル | Method for producing tomatidine-containing extract |
| CN114848663A (en) * | 2022-05-09 | 2022-08-05 | 河南省人民医院 | Application of natural compound Solamargine and anti-HBV (hepatitis B virus) pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1107680C (en) | 2003-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100545164C (en) | The preparation technology of disodium cantharidinate | |
| CN101926801A (en) | Medicinal composition | |
| CN1241574C (en) | Medicine for relieving spasm and pain and preparation process thereof | |
| CN102786417B (en) | The brilliant type III of chlorogenic acid characterizes and preparation method and applying in medicine and healthcare products | |
| CN1382478A (en) | Extract of mulberry twig and its extracting process and novel usage | |
| CN1107680C (en) | Solasodine hydrochlorate and productive method and application in medicine | |
| CN102526349A (en) | Gel ointment as well as preparation method and application thereof | |
| CN1166669C (en) | Prepn process of sodium cantharidinate | |
| CN102228547B (en) | Application of traditional Chinese medicine composition in preparing medicaments treating pancreatitis and/or cholecystitis | |
| CN101411779B (en) | Chinese medicine effective component composition for treating liver cancer and method for preparing the same | |
| CN1771978A (en) | Notoginseng triol-saponin composition and its prepn and use | |
| CN1312170C (en) | Technique of preparing extract product of Radde Anemone Rhizome extract, and its application in preparing medication of treating cancer | |
| CN1193766C (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method | |
| CN101633661B (en) | Process for preparing sodium cantharidinate | |
| CN101301304A (en) | Chinese medicinal composition for treating ischemic stroke and preparation thereof | |
| CN1426783A (en) | Application of evodiamine in the preparation of medicine | |
| CN102552383A (en) | Compound jellyfish antihypertensive dispersible tablet and preparation method thereof | |
| CN1679797A (en) | Anti-cancer Tengli root extract and its making method and use | |
| CN111714521B (en) | Periplaneta americana intestinal flora metabolite extract, preparation method thereof and application thereof in preparing anti-inflammatory or anti-ulcer products | |
| CN1079396A (en) | Intelligence-enhancing pharmaceutical preparation | |
| CN115364179B (en) | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof | |
| CN102499913A (en) | Preparation method for refined and purified paeonol preparation | |
| CN1089243C (en) | Medicine for promoting digestion function of stomach and intestine | |
| CN1182151C (en) | Method for purifying Huanweihuangyangxing D and preparation thereof | |
| CN100421685C (en) | Chinese material medica preparation in use for treating infection of influenza virus, and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JILIN ZHUOYIKANGNA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LIU LIANG Effective date: 20031219 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20031219 Address after: 132013 No. 7-1, Xiamen street, hi tech Zone, Jilin, Jilin, Jilin Patentee after: Jilin City Zhuoyikangna pharmaceutical Co., Ltd. Address before: 1 Department of organic chemistry, School of medicine, Beihua University, Beijing Road, Jilin, Jilin 132011, China Patentee before: Liu Liang |
|
| DD01 | Delivery of document by public notice |
Addressee: Jilin City Zhuoyikangna pharmaceutical Co., Ltd. Document name: Notification of Termination of Patent Right |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20030507 Termination date: 20150929 |
|
| EXPY | Termination of patent right or utility model |